Meriva® 	Meriva® 	 NNP	B-NP
,  	,  	 ,	O
a  	a  	 DT	O
lecithinized  	lecithinized  	 JJ	B-NP
curcumin  	curcumin  	 JJ	I-NP
delivery  	delivery  	 NN	I-NP
system 	system 	 NN	I-NP
,  	,  	 ,	O
in  	in  	 IN	O
the  	the  	 DT	O
control  	control  	 NN	O
of  	of  	 IN	O
benign  	benign  	 JJ	O
prostatic  	prostatic  	 JJ	B-NP
hyperplasia 	hyperplasia 	 NN	I-NP
:  	:  	 :	O
a  	a  	 DT	O
pilot 	pilot 	 NN	O
,  	,  	 ,	O
product  	product  	 NN	B-NP
evaluation  	evaluation  	 NN	I-NP
registry  	registry  	 NNS	I-NP
study  	study  	 VBP	O
The  	The  	 DT	O
aim  	aim  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
registry  	registry  	 JJ	B-NP
evaluation  	evaluation  	 NN	I-NP
study  	study  	 NN	I-NP
was  	was  	 VBD	O
to  	to  	 TO	O
compare 	compare 	 VB	O
,  	,  	 ,	O
in  	in  	 IN	O
symptomatic  	symptomatic  	 JJ	B-NP
BPH  	BPH  	 NN	I-NP
patients 	patients 	 NNS	I-NP
,  	,  	 ,	O
two  	two  	 CD	O
management  	management  	 NN	O
plans  	plans  	 VBZ	O
based  	based  	 VBN	O
on  	on  	 IN	O
a  	a  	 DT	O
currently  	currently  	 RB	O
validated  	validated  	 JJ	O
standard  	standard  	 JJ	O
treatment  	treatment  	 NN	O
[ 	[ 	 -LRB-	O
defined  	defined  	 VBN	O
as  	as  	 IN	O
the  	the  	 DT	O
best  	best  	 RBS	B-NP
standard  	standard  	 JJ	I-NP
management  	management  	 NN	I-NP
( 	( 	 -LRB-	O
BSM 	BSM 	 NNP	B-NP
) 	) 	 -RRB-	O
]  	]  	 -RRB-	O
including  	including  	 VBG	O
or  	or  	 CC	O
not  	not  	 RB	O
curcumin  	curcumin  	 JJ	O
( 	( 	 -LRB-	O
administered  	administered  	 VBN	O
as  	as  	 IN	O
Meriva® 	Meriva® 	 CD	B-NP
)  	)  	 -RRB-	O
as  	as  	 IN	O
a  	a  	 DT	O
further  	further  	 JJ	O
complementary  	complementary  	 JJ	B-NP
adjuvant  	adjuvant  	 JJ	I-NP
element 	element 	 NN	I-NP
.  	.  	 .	O
Signs  	Signs  	 NNS	O
and  	and  	 CC	O
symptoms  	symptoms  	 NNS	B-NP
were  	were  	 VBD	O
evaluated  	evaluated  	 VBN	O
using  	using  	 VBG	O
the  	the  	 DT	O
International  	International  	 NNP	B-NP
Prostate  	Prostate  	 NNP	I-NP
Symptom  	Symptom  	 NNP	I-NP
Score  	Score  	 NNP	I-NP
( 	( 	 -LRB-	O
IPSS 	IPSS 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
SUBJECTS 	SUBJECTS 	 NNS	B-NP
,  	,  	 ,	O
METHODS 	METHODS 	 NNP	O
:  	:  	 :	O
The  	The  	 DT	O
study  	study  	 NN	O
was  	was  	 VBD	O
carried  	carried  	 VBN	O
out  	out  	 RP	O
on  	on  	 IN	O
a  	a  	 DT	O
total  	total  	 NN	O
of  	of  	 IN	O
61  	61  	 CD	O
subjects.  	subjects.  	 CD	B-NP
33  	33  	 CD	O
subjects  	subjects  	 NNS	B-NP
( 	( 	 -LRB-	O
mean  	mean  	 JJ	O
age  	age  	 NN	O
58.6 	58.6 	 CD	O
; 	; 	 :	O
5.3 	5.3 	 CD	O
)  	)  	 -RRB-	O
completed  	completed  	 VBD	O
the  	the  	 DT	O
survey  	survey  	 NN	O
with  	with  	 IN	O
at  	at  	 IN	O
least  	least  	 JJS	O
24  	24  	 CD	O
weeks  	weeks  	 NNS	O
of  	of  	 IN	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
Meriva®  	Meriva®  	 CD	B-NP
in  	in  	 IN	O
association  	association  	 NN	O
with  	with  	 IN	O
the  	the  	 DT	O
BSM 	BSM 	 NNP	B-NP
.  	.  	 .	O
The  	The  	 DT	O
BSM-alone  	BSM-alone  	 JJ	B-NP
control  	control  	 NN	I-NP
group  	group  	 NN	I-NP
consisted  	consisted  	 VBD	O
of  	of  	 IN	O
28  	28  	 CD	O
volunteers  	volunteers  	 NNS	O
of  	of  	 IN	O
similar  	similar  	 JJ	O
age  	age  	 NN	O
( 	( 	 -LRB-	O
58.4  	58.4  	 CD	O
years 	years 	 NNS	O
; 	; 	 :	O
3.4 	3.4 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
severity  	severity  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
condition 	condition 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
range  	range  	 NN	O
of  	of  	 IN	O
inclusion  	inclusion  	 JJ	B-NP
age  	age  	 NN	I-NP
was  	was  	 VBD	O
55-65 	55-65 	 CD	O
.  	.  	 .	O
No  	No  	 DT	O
other  	other  	 JJ	O
clinical  	clinical  	 JJ	O
or  	or  	 CC	O
metabolic  	metabolic  	 JJ	B-NP
problems  	problems  	 NNS	I-NP
were  	were  	 VBD	O
present 	present 	 JJ	O
.  	.  	 .	O
Meriva®  	Meriva®  	 NNP	B-NP
was  	was  	 VBD	O
administered  	administered  	 VBN	O
at  	at  	 IN	O
the  	the  	 DT	O
dosage  	dosage  	 NN	O
of  	of  	 IN	O
2  	2  	 CD	O
tablets 	tablets 	 CD	B-NP
/ 	/ 	 CD	I-NP
day  	day  	 NN	I-NP
( 	( 	 -LRB-	O
2  	2  	 CD	O
x  	x  	 SYM	O
500  	500  	 CD	O
mg  	mg  	 NN	B-NP
of  	of  	 IN	I-NP
Meriva® 	Meriva® 	 CD	I-NP
/ 	/ 	 CD	O
day 	day 	 NN	O
,  	,  	 ,	O
corresponding  	corresponding  	 JJ	O
to  	to  	 TO	O
2  	2  	 CD	O
x  	x  	 SYM	O
100  	100  	 CD	O
mg  	mg  	 CD	B-NP
curcumin 	curcumin 	 CD	I-NP
/ 	/ 	 CD	I-NP
day 	day 	 NN	I-NP
)  	)  	 -RRB-	O
with  	with  	 IN	O
a  	a  	 DT	O
compliance  	compliance  	 NN	O
values  	values  	 VBZ	O
>  	>  	 CD	O
95 	95 	 CD	O
%  	%  	 NN	O
as  	as  	 IN	O
evaluated  	evaluated  	 NN	O
by  	by  	 IN	O
the  	the  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
tablets  	tablets  	 NNS	O
used  	used  	 VBN	O
according  	according  	 VBG	O
to  	to  	 TO	O
medical  	medical  	 JJ	B-NP
recommendation 	recommendation 	 NN	I-NP
.  	.  	 .	O
No  	No  	 DT	O
other  	other  	 JJ	O
drugs  	drugs  	 NNS	O
or  	or  	 CC	O
food  	food  	 NN	B-NP
supplement  	supplement  	 NN	I-NP
were  	were  	 VBD	O
used  	used  	 VBN	O
during  	during  	 IN	O
the  	the  	 DT	O
study 	study 	 NN	O
.  	.  	 .	O
All  	All  	 DT	O
IPSS  	IPSS  	 NNP	B-NP
scores 	scores 	 NNS	I-NP
,  	,  	 ,	O
with  	with  	 IN	O
the  	the  	 DT	O
exception  	exception  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
stream  	stream  	 NN	B-NP
weakness  	weakness  	 NN	I-NP
score  	score  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
BSM  	BSM  	 NNP	B-NP
group 	group 	 NN	I-NP
,  	,  	 ,	O
were  	were  	 VBD	O
improved  	improved  	 VBN	O
( 	( 	 -LRB-	O
p  	p  	 FW	O
< 	< 	 SYM	O
0.05  	0.05  	 FW	O
vs.  	vs.  	 FW	O
inclusion 	inclusion 	 FW	O
)  	)  	 -RRB-	O
in  	in  	 IN	O
both  	both  	 DT	O
groups 	groups 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
overall  	overall  	 JJ	O
results  	results  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
Meriva®  	Meriva®  	 JJ	O
group  	group  	 NN	O
were  	were  	 VBD	O
significantly  	significantly  	 RB	O
better  	better  	 JJR	O
than  	than  	 IN	O
in  	in  	 IN	O
the  	the  	 DT	O
BSM-only  	BSM-only  	 JJ	B-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
p  	p  	 CD	O
< 	< 	 SYM	O
0.05 	0.05 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
No  	No  	 DT	O
side  	side  	 NN	B-NP
effects  	effects  	 NNS	I-NP
were  	were  	 VBD	O
recorded 	recorded 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
quality  	quality  	 NN	O
of  	of  	 IN	O
life  	life  	 NN	O
improved  	improved  	 VBN	O
in  	in  	 IN	O
both  	both  	 DT	O
groups 	groups 	 NNS	O
,  	,  	 ,	O
but  	but  	 CC	O
was  	was  	 VBD	O
significantly  	significantly  	 RB	O
better  	better  	 JJR	O
in  	in  	 IN	O
the  	the  	 DT	O
Meriva®  	Meriva®  	 JJ	O
group  	group  	 NN	O
( 	( 	 -LRB-	O
p  	p  	 CD	O
< 	< 	 SYM	O
0.01 	0.01 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
There  	There  	 EX	O
was  	was  	 VBD	O
also  	also  	 RB	O
a  	a  	 DT	O
significantly  	significantly  	 RB	O
more  	more  	 RBR	O
important  	important  	 JJ	O
decrease  	decrease  	 NN	O
in  	in  	 IN	O
clinical  	clinical  	 JJ	O
and  	and  	 CC	O
subclinical  	subclinical  	 JJ	B-NP
episodes  	episodes  	 NNS	I-NP
of  	of  	 IN	I-NP
urinary  	urinary  	 JJ	I-NP
infections  	infections  	 NNS	I-NP
and  	and  	 CC	O
urinary  	urinary  	 JJ	B-NP
block  	block  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
Meriva®  	Meriva®  	 JJ	O
group  	group  	 NN	O
( 	( 	 -LRB-	O
p  	p  	 CD	O
< 	< 	 SYM	O
0.01 	0.01 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
BPH 	BPH 	 NNP	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
addition  	addition  	 NN	B-NP
of  	of  	 IN	I-NP
Meriva®  	Meriva®  	 CD	I-NP
to  	to  	 TO	O
the  	the  	 DT	O
standard  	standard  	 JJ	O
treatment  	treatment  	 NN	O
contributed  	contributed  	 VBD	O
to  	to  	 TO	O
the  	the  	 DT	O
reduction  	reduction  	 NN	O
of  	of  	 IN	O
signs  	signs  	 NNS	O
and  	and  	 CC	O
symptoms  	symptoms  	 NNS	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
disease  	disease  	 NN	O
without  	without  	 IN	O
causing  	causing  	 VBG	O
any  	any  	 DT	O
significant  	significant  	 JJ	O
additional  	additional  	 JJ	O
side  	side  	 NN	B-NP
effect 	effect 	 NN	I-NP
.  	.  	 .	O
This  	This  	 DT	O
pilot  	pilot  	 NN	O
experience  	experience  	 NN	O
suggests  	suggests  	 VBZ	O
a  	a  	 DT	O
potential  	potential  	 JJ	B-NP
novel  	novel  	 NN	I-NP
clinical  	clinical  	 JJ	I-NP
application  	application  	 NN	I-NP
of  	of  	 IN	O
curcumin 	curcumin 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
further  	further  	 JJ	O
studies  	studies  	 NNS	O
aimed  	aimed  	 VBN	O
at  	at  	 IN	O
selecting  	selecting  	 VBG	O
the  	the  	 DT	O
most  	most  	 RBS	O
appropriate  	appropriate  	 JJ	O
dosages  	dosages  	 NN	O
and  	and  	 CC	O
length  	length  	 NN	O
of  	of  	 IN	O
treatment  	treatment  	 NN	O
as  	as  	 IN	O
well  	well  	 RB	O
as  	as  	 IN	O
the  	the  	 DT	O
possibility  	possibility  	 NN	O
to  	to  	 TO	O
including  	including  	 VBG	O
longer  	longer  	 JJR	O
treatments  	treatments  	 NNS	O
will 	will 	 MD	O
,  	,  	 ,	O
undoubtedly 	undoubtedly 	 RB	O
,  	,  	 ,	O
validate  	validate  	 NN	O
and  	and  	 CC	O
optimize  	optimize  	 VBG	O
the  	the  	 DT	O
role  	role  	 NN	O
of  	of  	 IN	O
Meriva®  	Meriva®  	 CD	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
management  	management  	 NN	O
of  	of  	 IN	O
BPH 	BPH 	 NNP	B-NP
.  	.  	 .	O
